ImmunityBio (IBRX) Amortization of Deferred Charges (2021 - 2026)

ImmunityBio (IBRX) has 6 years of Amortization of Deferred Charges data on file, last reported at $956000.0 in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 45.29% year-over-year to $956000.0 in Q1 2026; TTM through Mar 2026 was $298000.0, a 98.32% decrease from a year earlier, with the FY2024 full-year figure at $22.6 million, down 46.72% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $956000.0, up from -$658000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for IBRX reached as high as $37.6 million in Q4 2023 and fell as low as -$658000.0 in Q2 2025.
• Historically, Amortization of Deferred Charges has averaged $5.5 million across 5 years, with a median of $1.6 million in 2023.
• Across the five-year window, Amortization of Deferred Charges soared 449.1% in 2022 and sank 111.28% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $12.0 million in 2022, then jumped by 213.36% to $37.6 million in 2023, then sank by 86.69% to $5.0 million in 2024, then plunged by 113.14% to -$658000.0 in 2025, then soared by 245.29% to $956000.0 in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $956000.0 in Q1 2026, -$658000.0 in Q2 2025, and $658000.0 in Q1 2025.